Ghost Tree Capital’s Sage Therapeutics SAGE Stock Holding History

Ghost Tree Capital’s Portfolio SAGE Stock Details SAGE Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q1	–	Sell	-150,000	Closed	-$10.8M	–	60
2019 Q4	$10.8M	Buy	+150,000	New	+$18.5M	2.06%	16
2019 Q1	–	Sell	-30,000	Closed	-$2.87M	–	42
2018 Q4	$2.87M	Buy	+30,000	New	+$3.43M	1.04%	29
2016 Q3	–	Sell	-150,000	Closed	-$4.52M	–	96
2016 Q2	$4.52M	Buy	+150,000	New	+$5M	1.31%	31
2015 Q3	–	Sell	-31,700	Closed	-$2.31M	–	90
2015 Q2	$2.31M	Buy	+31,700	New	+$2.04M	0.75%	50

Other funds holding SAGE

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Bellevue Group Kuesnacht, Switzerland $4.2B AUM 54.85% 1-Year Est. Return

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Artisan Partners Milwaukee, Wisconsin $62.3B AUM 26.25% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return

Ghost Tree Capital's SAGE Position: Q2 2021 in Review

Ghost Tree Capital sold out of Sage Therapeutics (SAGE) in Q2 2021, closing a stake of 30,000 shares — an estimated $2.25M sold.

Ghost Tree Capital first reported a position in SAGE in Q1 2015 and held it in 18 quarters. The position peaked at $15.4M in Q3 2019. 256 funds tracked by Wall St. Rank hold SAGE as of Q2 2021.

Ghost Tree Capital reported no remaining Sage Therapeutics position as of Q2 2021 after selling out during the quarter.
Ghost Tree Capital sold 30,000 Sage Therapeutics shares in Q2 2021, an estimated $2.25M.
Ghost Tree Capital first reported a position in Sage Therapeutics in Q1 2015 and held it in 18 quarters.
Ghost Tree Capital's Sage Therapeutics position peaked at $15.4M in Q3 2019.
256 funds tracked by Wall St. Rank held Sage Therapeutics as of Q2 2021.

Based on Ghost Tree Capital's 13F filing for Q2 2021, filed 11 Aug 2021.